PMID- 12627850
OWN - NLM
STAT- MEDLINE
DCOM- 20030605
LR  - 20220331
IS  - 0925-5710 (Print)
IS  - 0925-5710 (Linking)
VI  - 77
IP  - 2
DP  - 2003 Feb
TI  - Multicenter prospective study of clonal complications in adult aplastic anemia 
      patients following recombinant human granulocyte colony-stimulating factor 
      (lenograstim) administration.
PG  - 152-8
AB  - To elucidate the relationship between treatment with granulocyte 
      colony-stimulating factor (G-CSF) and the development of chromosomal 
      abnormalities and clonal evolution in adult aplastic anemia (AA) patients, we 
      performed a prospective multicenter study. Of the 104 registered patients, 91 
      were found by the central review committee to have the diagnosis of AA. Of the 91 
      patients, 84 were determined to be evaluable in this study and were treated with 
      regimens including G-CSF (lenograstim). A time-course study (at registration and 
      6 and 12 months after registration) of G-banded chromosomes, fluorescence in situ 
      hybridization (FISH) analysis for monosomy 7, and morphological assessment of 
      bone marrow was performed with these patients during the 1-year follow-up period. 
      G-banding analysis demonstrated the development of cytogenetic abnormalities in 
      10 (16.1%) of the 62 evaluable patients. The most common aberration was monosomy 
      7. FISH analysis demonstrated monosomy 7 in 7 (10.4%) of the 67 evaluable 
      patients. Evolution into myelodysplastic syndrome (MDS) was observed in 5 (7.7%) 
      of the 65 patients who underwent morphological assessment of bone marrow. All 
      patients who developed cytogenetic abnormalities or MDS received 
      immunosuppressive agents and/or steroids with G-CSF. This study demonstrated that 
      some adult AA patients exhibit evolution into MDS and development of chromosomal 
      abnormalities such as monosomy 7. Although the incidence seems to be comparable 
      with that found in previous studies, further long-term follow-up will be 
      necessary to confirm the relationship between G-CSF and the development of 
      chromosomal abnormalities and MDS.
FAU - Bessho, Masami
AU  - Bessho M
AD  - First Department of Internal Medicine, Saitama Medical School, Iruma-gun, 
      Saitama, Japan. hbesshoo@saitama-med.ac.jp
FAU - Hotta, Tomomitsu
AU  - Hotta T
FAU - Ohyashiki, Kazuma
AU  - Ohyashiki K
FAU - Takahashi, Takayuki
AU  - Takahashi T
FAU - Mizoguchi, Hideaki
AU  - Mizoguchi H
FAU - Asano, Shigetaka
AU  - Asano S
FAU - Ikeda, Yasuo
AU  - Ikeda Y
FAU - Sakurai, Masaharu
AU  - Sakurai M
FAU - Tojo, Arinobu
AU  - Tojo A
FAU - Kizaki, Masahiro
AU  - Kizaki M
FAU - Iwanaga, Masako
AU  - Iwanaga M
FAU - Tomonaga, Masao
AU  - Tomonaga M
FAU - Hirashima, Kunitake
AU  - Hirashima K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Recombinant Proteins)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia, Aplastic/drug therapy/*pathology
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 7
MH  - Clone Cells/drug effects/pathology
MH  - Cytogenetic Analysis
MH  - Female
MH  - Follow-Up Studies
MH  - Granulocyte Colony-Stimulating Factor/administration & dosage/*toxicity
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monosomy
MH  - Myelodysplastic Syndromes/chemically induced
MH  - Prospective Studies
MH  - Recombinant Proteins
MH  - Time Factors
EDAT- 2003/03/12 04:00
MHDA- 2003/06/06 05:00
CRDT- 2003/03/12 04:00
PHST- 2003/03/12 04:00 [pubmed]
PHST- 2003/06/06 05:00 [medline]
PHST- 2003/03/12 04:00 [entrez]
PST - ppublish
SO  - Int J Hematol. 2003 Feb;77(2):152-8.